Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients

Archives of Pharmacal Research

Volumn 26, Issue 11, 2003, Pages 967-972

  Lee, Sukhyang ^a   Kim, Jae Moon ^b   Chung, Chin Sang ^c   Cho, Kyoung Joo ^d   Kim, Jeong Hee ^d  

^a Sookmyung Women's University   (South Korea)

^b Chungnam National University College of Medicine   (South Korea)

^c Samsung Medical Center   (South Korea)

^d Kyung Hee University   (South Korea)

Author keywords

CYP2C9; Polymorphism; Warfarin

Indexed keywords

CYP2C9 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE; WARFARIN;

AGED; ANALYSIS OF VARIANCE; ARTICLE; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; GENOTYPE; HUMAN; KOREA; MALE; MIDDLE AGED; PROTHROMBIN TIME; STATISTICS;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ARYL HYDROCARBON HYDROXYLASES; CHI-SQUARE DISTRIBUTION; FEMALE; GENOTYPE; HUMANS; KOREA; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTHROMBIN TIME; VARIATION (GENETICS); WARFARIN;

EID: 3042544054     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/BF02980207     Document Type: Article

References (16)

1. Aithal, G. P., Day, C. P., Kesteven, P. J. L., and Daly, A. K., Association of polymorphism in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.Lancet, 353, 717–719 (1999). DOI: 10.1016/S0140-6736(98)04474-2
2. Furuya, H, Femandez-Salguero, P., Gregory, W., Taber, H., Steward, A., Gonzalez, F., and Idle, J. R., Genetic polymorphism of CYP2C9 and its effects on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.Pharmacogenetics, 5, 389–392 (1995). DOI: 10.1097/00008571-199512000-00008
3. Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., and Ansell, J.,et al., Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 114, 445S-469S (1998).
4. James, A. H., Britt, R. P., Risking, C. L., and Thompson, S. G., Factors affecting the maintenance dose of warfarin.J. Clin. Pathol., 45, 704–706 (1992). DOI: 10.1136/jcp.45.8.704
5. Kaminsky, L. S. and Zhang, Z.-Y., Human p450 metabolism of warfarin.Pharmacol. Ther., 73, 67–74 (1997). DOI: 10.1016/S0163-7258(96)00140-4
6. Kimura, M., leiri, I., Mamiya, K., Urae, A., and Higuchi, S., Genetic polymorphism of cytochrome P450s, CYP2C19 and CYP in a Japanese population.Ther. Drug. Monit., 20, 243–247 (1998). DOI: 10.1097/00007691-199806000-00001
7. Landefeld, C. S. and Beyth, R. J., Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.Am. J. Med., 95, 315–328 (1993). DOI: 10.1016/0002-9343(93)90285-W
8. Miners, J. O. and Birkett, D. J., Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.Br. J. Clin. Pharmacol., 45, 277–280 (1998). DOI: 10.1046/j.1365-2125.1998.00721.x
9. Nasu, K., Kubota, T., and Ishizaki, T., Genetic analysis of CYP2C9 polymorphism in a Japanese population.Pharmacogenetics, 7, 405–409 (1997). DOI: 10.1097/00008571-199710000-00011
10. Redman, A. R., Implications of cytochrome P4502C9 polymorphism on warfarin metabolism and dosing.Pharmacotherapy, 21, 235–242 (2001). DOI: 10.1592/phco.21.2.235.34106
11. Rettie, A. E., Wienkers, L. C., Gonzalez, F. J., Trager, W. F., and Korzekwa, K. R., Impaired S-warfarin metabolism catalyzed by R144C allelic variant of CYP2C9.Pharmacogenetics, 4, 39–42 (1994). DOI: 10.1097/00008571-199402000-00005
12. Stubbins, M. J., Harries, L. W., Smith, G., Tarbit, M. H., and Wolf, C. R., Genetic analysis of the human cytochrome P450 CYP2C9 locus.Pharmacogenetics, 6, 429–439 (1996). DOI: 10.1097/00008571-199610000-00007
13. Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z.-Y., Kaminsky, L. S., and Shenfield, G. M.,et al., The role of the CYP2C9-Leu359 allelic variant in the tolbutamice polymorphism.Pharmacogentics, 6, 341–349 (1996). DOI: 10.1097/00008571-199608000-00007
14. Takahashi, H., Kashima, T., Momizo, Y., Muramoto, N., Shimizu, T., and Nasu, K.,et al., Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.Clin Pharmacol. Ther., 63, 519–528 (1998). DOI: 10.1016/S0009-9236(98)90103-5
15. Wang, S. L., Huang, J.-D., Lai, M. D., and Tsai, J. J., Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese.Pharmacogenetics, 5, 37–42 (1995). DOI: 10.1097/00008571-199502000-00004
16. Yoon, Y. R., Shon, J. H., Kim, M. K., Lim, Y. C., Lee, H. R., Park, J. Y., Cha, I. J., and Shin, J. G., Frequency of cytochorome P450 2C9 mutant alleles in a Korean population.Br. J. Clin. Pharmacol., 51, 277–280 (2001). DOI: 10.1046/j.1365-2125.2001.00340.x